Literature DB >> 28796371

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011.

Jakob Ørskov Sørensen1, Ole Haagen Nielsen2, Mikael Andersson1, Mark Andrew Ainsworth2, Henriette Ytting3, Erika Bélard2, Tine Jess1,4.   

Abstract

BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) may be complicated by primary sclerosing cholangitis (PSC). We aimed to assess the characteristics of Danish PSC-IBD patients and to compare their prognosis with IBD patients without PSC.
METHODS: A retrospective nationwide population-based cohort of 257 PSC-IBD patients was assessed through Danish national registries and manual scrutiny of patient files.
RESULTS: For all PSC-IBD patients diagnosed after 1976 (n = 222) and 8231 IBD controls (ie, without PSC), the cumulative probability of resective surgery, liver transplantation, cancer, and survival from 1977 through 2011 was estimated and compared by log-rank test and Cox regression. PSC-IBD patients primarily had ulcerative colitis (UC) (72%), were diagnosed in young adulthood (median age at IBD diagnosis, 23 years), and 9% were smokers. Among PSC-UC patients 78% had pancolitis at diagnosis. Among patients with PSC and Crohn's disease (CD) 91% had colonic involvement. The PSC-IBD patients had a significantly higher probability of receiving resective surgery (HR; 2.13, 95% CI: 1.50-3.03); of developing colorectal cancer (CRC) (HR; 21.4, 95% CI: 9.6-47.6), of cholangiocarcinoma (HR; 190, 95% CI: 54.8-660), and of dying (HR; 4.39, 95% CI: 3.22-6.00) as compared to non-PSC-IBD controls. The 25-year cumulative risk of liver transplantation was high (53%).
CONCLUSIONS: This unselected population-based study shows that PSC-IBD patients not only have an extensive phenotype of IBD, they are also treated more intensively than other patients with IBD. However, the prognosis remains poor and without any apparent improvement over calendar time.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  epidemiology; inflammatory bowel disease; primary sclerosing cholangitis; prognosis

Mesh:

Year:  2017        PMID: 28796371     DOI: 10.1111/liv.13548

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

Review 1.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

2.  Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease.

Authors:  Manon de Krijger; Thijmen Visseren; Manon E Wildenberg; Gerrit K J Hooijer; Monique M A Verstegen; Luc J W van der Laan; Wouter J de Jonge; Joanne Verheij; Cyriel Y Ponsioen
Journal:  J Transl Autoimmun       Date:  2020-04-09

Review 3.  Pancreatic Disorders in Patients with Inflammatory Bowel Disease.

Authors:  Marilia L Montenegro; Juan E Corral; Frank J Lukens; Baoan Ji; Paul T Kröner; Francis A Farraye; Yan Bi
Journal:  Dig Dis Sci       Date:  2021-02-24       Impact factor: 3.199

Review 4.  Challenging biliary strictures: pathophysiological features, differential diagnosis, diagnostic algorithms, and new clinically relevant biomarkers - part 1.

Authors:  Jean-Marc Dumonceau; Myriam Delhaye; Nicolas Charette; Annarita Farina
Journal:  Therap Adv Gastroenterol       Date:  2020-06-16       Impact factor: 4.409

5.  The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.

Authors:  Charles N Bernstein; Eric I Benchimol; Alain Bitton; Sanjay K Murthy; Geoffrey C Nguyen; Kate Lee; Jane Cooke-Lauder; Gilaad G Kaplan
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

6.  Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients.

Authors:  Junichiro Kumagai; Takashi Taida; Sadahisa Ogasawara; Tomoo Nakagawa; Yotaro Iino; Ayako Shingyoji; Kentaro Ishikawa; Naoki Akizue; Mutsumi Yamato; Koji Takahashi; Yuki Ohta; Shinsaku Hamanaka; Kenichiro Okimoto; Masato Nakamura; Hiroshi Ohyama; Keiko Saito; Yuko Kusakabe; Daisuke Maruoka; Shin Yasui; Tomoaki Matsumura; Harutoshi Sugiyama; Yuji Sakai; Rintaro Mikata; Makoto Arai; Tatsuro Katsuno; Toshio Tsuyuguchi; Naoya Kato
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

Review 7.  Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence.

Authors:  Andrew Mertz; Nhu An Nguyen; Konstantinos H Katsanos; Ryan M Kwok
Journal:  Ann Gastroenterol       Date:  2019-01-15

Review 8.  Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms.

Authors:  Sukanya Roy; Shannon Glaser; Sanjukta Chakraborty
Journal:  Front Med (Lausanne)       Date:  2019-12-18

9.  The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival.

Authors:  Daljeet Chahal; Chris Shamatutu; Bill Salh; Janine Davies
Journal:  JGH Open       Date:  2020-08-11

10.  Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease.

Authors:  Mohamed Attauabi; Mirabella Zhao; Flemming Bendtsen; Johan Burisch
Journal:  Therap Adv Gastroenterol       Date:  2021-06-22       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.